ClinicalTrials.gg
Enrolling by invitationNCT06041984Updated Dec 8, 2023

Antiperistaltic Effect and Safety of Glycopyrronium for Colonoscopic Polypectomy

A Phase 1/2 interventional study of Glycopyrrolate and Placebo in Glycopyrrolate and Colonoscopy, sponsored by Jie Chen. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-08.

Sponsored by Jie Chen · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 7 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to determine the antiperistaltic effect and safety of glycopyrrolate and whether the use of glycopyrrolate is beneficial for colonoscopy and colonoscopic polypectomy.

Read the detailed description

Colonic spasm is a major adverse event affecting colonoscopy.The current mainstay for the prevention of colonic spasm is the use of antispasmodic.Glycopyrrolate is a long-acting quaternary ammonium anticholinergic drug.The study is designed as a randomized, double-blind, placebo-controlled study of the efficacy and safety of glycopyrrolate in participants receiving colonoscopy and colonoscopic polypectomy. Patients at our center who met the inclusion criteria were randomized into the glycopyrrolate group and the placebo group, and then statistically analyzed whether there was any difference in the incidence of spasticity, spasticity scores, polyp treatment time, and satisfaction with endoscopist operation between the two groups.

02

Conditions studied

  • Glycopyrrolate
  • Colonoscopy
03

In context

Lead sponsor

Jie Chen is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80 years old.
  • Outpatients and inpatients with lesions to be resected under colonoscopy.
  • Participants voluntarily participated and signed forms.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy status and lactating women.
  • With glaucoma, myasthenia gravis, hyperthyroidism, chronic renal insufficiency, and inflammatory bowel disease.
  • With obstructive gastrointestinal diseases such as pyloric obstruction, paralytic ileus, and achalasia of the cardia.
  • With obstructive urinary tract diseases such as prostatic hyperplasia and dysuria.
  • With heart disease such as arrhythmia (bradycardia, tachycardia, ventricular fibrillation, atrial fibrillation, etc.), coronary heart disease, congestive heart failure.
  • With a history of previous abdominal or intestinal surgery.
  • Anticholinergic drugs were administered 48 hours before surgery.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Glycopyrrolate

    Participants will receive intravenous glycopyrrolate 0.2 mg while receiving anesthetic.

    Drug: Glycopyrrolate

  • Placebo comparator
    Placebo

    Participants will receive intravenous 1ml saline while receiving anesthetic.

    Other: Placebo

Interventions

  • Intravenous injection of glycopyrrolate 0.2mg

  • OtherPlacebo

    Intravenous injection of saline 1ml

06

What researchers measure

Primary outcomes

  1. Incidence of intestinal spasm

    The incidence of intestinal spasm in the two groups was calculated after determining whether colonic spasms occurred according to the inhibitory effect score.Rated on a scale of 1 to 3 according to the luminal opening diameter:1 (excellent): no spasm,lumen opening ≥ 2/3 of maximum diameter, 2 (fair): moderate spasm,lumen opening \< 2/3 of maximum diameter, but the oral side can be seen and 3 (poor): severe spasm,the oral side lumen is not visible.

    Time frame: During Colonoscopy

Secondary outcomes

  1. inhibitory effect score

    Rated on a scale of 1 to 3 according to the luminal opening diameter:1 (excellent): no spasm,lumen opening ≥ 2/3 of maximum diameter, 2 (fair): moderate spasm,lumen opening \< 2/3 of maximum diameter, but the oral side can be seen and 3 (poor): severe spasm,the oral side lumen is not visible.

    Time frame: During Colonoscopy

  2. Polyp Treatment Time

    Time from start of polyp removal to complete polyp removal.

    Time frame: During Colonoscopy

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Apr 2024, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2023
First posted
Sep 18, 2023
StartActual
Oct 8, 2023
Primary completionEst.
Apr 2024
CompletionEst.
Jun 2024
Last update
Dec 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06041984
Lead sponsor
Jie Chen
Responsible party
Jie Chen (Clinical Professor, The Second Affiliated Hospital of Chongqing Medical University) — Sponsor-investigator
First posted
Sep 18, 2023
Start date
Oct 8, 2023
Primary completion
Apr 2024 (estimated)
Completion
Jun 2024 (estimated)
Last update
Dec 8, 2023

Study contacts

Guangyou Duan, doctor
study director · The Second Affiliated Hospital of Chongqing Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion